Immunome Inc. (IMNM)
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Immunome, Inc.
NASDAQ:IMNMHealthcare · Biotechnology
-0.44%$18.21
AH$18.88+3.66%vs close
Mkt Cap$2.15B
Float101.21M
O/S118M
Vol
$ Vol
RVOL
Inst Own100.0%
SI17.1%
Earnings
Dilution
Financials Summary
Revenue$6.94M
Net Income-$212.39M
Total Assets$683.19M
Free Cash Flow-$200.6M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$3.85M
Total Equity$634.34M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:1,000Reverse splitDec 19, 20071,000 shares → 1
Balance Sheet Details
Assets$683.19M
Liabilities$48.84M
Accounts Receivable$0
Accounts Payable$3.34M
Inventory$0
PP&E (Net)$17.61M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $6.94M | $9.04M | $14.02M | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -23.2% | -35.5% | - | - | - | - | - | - |
| Cost of Revenue | $2.96M | $0 | $0 | $0 | $0 | $755K | $615K | $521K |
| Gross Profit | $3.99M | $9.04M | $14.02M | $0 | $0 | -$755K | -$615K | -$521K |
| Gross Margin | 57.4% | 100.0% | 100.0% | - | - | - | - | - |
| Research and Development | $174.33M | $129.54M | $23.09M | $23.27M | $14.11M | $6.73M | $8.82M | $6.88M |
| Selling, General, and Administrative | $43.77M | $32.95M | $19.66M | $13.63M | $11.09M | $4.78M | $1.52M | $866K |
| Other | $0 | $152.34M | $80.8M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $218.1M | $314.84M | $123.55M | $36.9M | $25.2M | $11.51M | $10.35M | $7.74M |
| Operating Income (EBIT) | -$214.11M | -$305.8M | -$109.53M | -$36.9M | -$25.2M | -$12.26M | -$10.35M | -$7.74M |
| Operating Margin | -3084.8% | -3382.4% | -781.4% | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $5K | $10K | $38K | $106K | $141K |
| Interest Income | $11.72M | $12.84M | $2.72M | $5K | $10K | $1K | $10K | $39K |
| Other Income (Expense) | $1.72M | $12.84M | $2.72M | $5K | $493K | -$5.58M | -$96K | -$102K |
| Income Before Tax (EBT) | -$212.39M | -$292.96M | -$106.81M | -$36.9M | -$24.71M | -$17.84M | -$10.44M | -$7.84M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $39K |
| Net Income | -$212.39M | -$292.96M | -$106.81M | -$36.9M | -$24.71M | -$17.84M | -$10.55M | -$7.84M |
| Net Income Margin | -3060.0% | -3240.4% | -761.9% | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -1.69 | -1.84 | -7.18 |
| Diluted EPS | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -1.69 | -1.84 | -7.18 |
| Weighted Average OS | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
| EBITDA | -$209.44M | -$151.35M | -$28M | -$36.26M | -$23.95M | -$17.04M | -$9.72M | -$7.18M |
| EBITDA Margin | -3017.4% | -1674.1% | -199.7% | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $653.48M | $143.35M | $98.68M | $20.32M | $49.23M | $39.77M | $2.54M | $1.6M |
| Short-Term Investments | $0 | $73.95M | $39.46M | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $653.48M | $217.3M | $138.14M | $20.32M | $49.23M | $39.77M | $2.54M | $1.6M |
| Accounts Receivable | $0 | $0 | $289K | $847K | $4.31M | $850K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $7.29M | $4.04M | $4.99M | $0 | $0 | $0 | $0 | $509K |
| Total Current Assets | $660.78M | $221.34M | $144.7M | $22.65M | $56.64M | $42.89M | $3.12M | $2.11M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $17.61M | $14.39M | $3.64M | $965K | $855K | $1.53M | $1.7M | $2.08M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $210K | $0 | $100K | $0 | $100K | $100K | $0 | $100K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $4.59M | $4.51M | $100K | $432K | $332K | $0 | $238K | $155K |
| Total Long-Term Assets | $22.41M | $18.9M | $3.84M | $1.4M | $1.29M | $1.63M | $1.94M | $2.34M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $683.19M | $240.24M | $148.54M | $24.05M | $57.92M | $44.52M | $5.06M | $4.45M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $3.34M | $14.19M | $3.31M | $2.4M | $3.08M | $1.19M | $548K | $473K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $479K | $212K | $225K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $6.94M | $10.49M | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $15.15M | $8M | $4.98M | $1.96M | $2.02M | $527K | $426K | $83K |
| Total Current Liabilities | $44.99M | $54.31M | $21.83M | $7.33M | $9.73M | $3.04M | $1.67M | $1.56M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $3.85M | $0 | $0 | $0 | $0 | $134K | $113K | $325K |
| Long-Term Unearned Revenue | $0 | $0 | $5.49M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | -$5.49M | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $5.49M | $0 | $12K | $8K | $38.91M | $27.53M |
| Total Long-Term Liabilities | $3.85M | $4.77M | $6.83M | $62K | $12K | $142K | $39.02M | $28.09M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $48.84M | $59.08M | $28.66M | $7.39M | $9.74M | $3.18M | $40.69M | $29.65M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $57.92M | $44.52M | $0 | $27.51M |
| Common Stock | $11K | $6K | $4K | $1K | $1K | $1K | $0 | $1K |
| Retained Earnings | -$728.16M | -$515.77M | -$222.81M | -$116M | -$79.11M | -$54.39M | -$36.56M | -$26.11M |
| Comprehensive Income & Other | $0 | $57K | $22K | $0 | -$57.92M | -$44.52M | $0 | -$904K |
| Other Stockholders' Equity | $1.36B | $696.93M | $342.69M | $132.65M | $127.29M | $95.74M | $927K | $907K |
| Total Equity | $634.34M | $181.16M | $119.88M | $16.65M | $48.19M | $41.34M | -$35.63M | -$25.2M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $683.19M | $240.24M | $148.54M | $24.05M | $57.92M | $44.52M | $5.06M | $4.45M |
| Supplementary Data | ||||||||
| Total Debt | $3.85M | $4.83M | $1.65M | $291K | $317K | $613K | $564K | $1.18M |
| Net Debt | -$649.63M | -$138.52M | -$97.03M | -$20.03M | -$48.91M | -$39.15M | -$1.98M | -$426K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$212.39M | -$292.96M | -$106.81M | -$36.9M | -$24.71M | -$17.84M | -$10.44M | -$7.84M |
| Depreciation & Amortization | $2.96M | $2.1M | $728K | $631K | $755K | $755K | $615K | $521K |
| Deferred Income Tax | $0 | $0 | $0 | -$7.27M | -$500K | $5.54M | $0 | $0 |
| Stock-Based Compensation | $25.69M | $15.75M | $6.22M | $5.33M | $3.45M | $621K | $14K | $11K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$9.16M | $9.53M | -$608K | -$677K | $1.78M | $504K | $75K | $146K |
| Other Working Capital | -$6.06M | $5.35M | $12.61M | $2.92M | $998K | -$1.71M | $137K | -$248K |
| Total Working Capital Change | -$15.23M | $14.87M | $12M | $2.24M | $2.78M | -$1.21M | $212K | -$102K |
| Other Non-Cash Items | $8.06M | $149.44M | $80.29M | $7.27M | $4K | -$2K | $3K | $9K |
| Net Cash from Operating | -$190.92M | -$110.79M | -$7.57M | -$28.69M | -$18.23M | -$12.13M | -$9.6M | -$7.41M |
| Investing Activities | ||||||||
| Capital Expenditures | -$9.69M | -$7.17M | -$831K | -$248K | -$79K | -$586K | -$233K | -$228K |
| Acquisitions | $0 | $0 | $9.28M | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$123.27M | -$186.56M | -$38.93M | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $200M | $155M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | -$6.25M | -$46.34M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $60.8M | -$85.06M | -$30.48M | -$248K | -$79K | -$586K | -$233K | -$228K |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | $113K | -$49K | -$6.19M | $551K |
| Common Stock Issuance | $640.36M | $250M | $34K | $32K | $27.23M | $44.85M | $4.62M | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | -$35K | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$9.47M | $116.37M | $0 | $656K | -$6M | $0 | $0 |
| Net Cash from Financing | $640.36M | $240.53M | $116.41M | $32K | $27.77M | $49.94M | $10.77M | -$551K |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $510.24M | $44.67M | $78.36M | -$28.91M | $9.46M | $37.22M | $941K | -$8.19M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$190.92M | -$110.79M | -$7.57M | -$28.69M | -$18.23M | -$12.13M | -$9.6M | -$7.41M |
| Capital Expenditure | -$9.69M | -$53.51M | -$831K | -$248K | -$79K | -$586K | -$233K | -$228K |
| Free Cash Flow | -$200.6M | -$164.3M | -$8.4M | -$28.94M | -$18.3M | -$12.72M | -$9.83M | -$7.63M |
| Cash at Beginning | $143.45M | $98.78M | $20.42M | $49.33M | $39.87M | $2.64M | $1.6M | $9.89M |
| Cash at End | $653.69M | $143.45M | $98.78M | $20.42M | $49.33M | $39.87M | $2.54M | $1.7M |